POS0757 COVID-19 INFECTION AND RECOVERY AMONGST PATIENTS WITH MODERATE-TO-SEVERE LUPUS DURING THE PANDEMIC: RESULTS FROM THE BILAG-BIOLOGICS REGISTER (BILAG-BR)

Background Patients with systemic lupus erythematosus (SLE) are thought to be at greater risk of severe COVID-19 illness and associated complications due a combination inherent aberrant immune responses, immunosuppressive medications co-morbidities. Objectives To review infections, hospitalisation recovery in real-world cohort patients moderate SLE high immunosuppressant use. Methods The British Isles Lupus Assessment Group Biologics Registry (BILAG-BR) is national prospective registry from the UK (2010-21) requiring significant therapies. BILAG-BR were invited complete paper or online questionnaire which consisted 17 questions assess prior infection their during pandemic. Questionnaires completed between 9 th Oct 2021 7 Jan 2022. Responses linked data collected BILAG-BR. Mortality study centres Office National Statistics Dec 2019-Jan Results Data first 202/1268 respond. predominately female (186, 92.1%), had median age 51 (IQR 38-61) years 37 centres. Previous therapy included rituximab (165, 81.7%), belimumab (33, 16.3%) cyclophosphamide (54, 26.7%). In past 12 months, over two thirds (138, 68.3%) received oral prednisolone (current dose 5mg [IQR 5-8mg] daily), almost third parental steroids (60, 29.7%). Self-reported diagnosis occurred 48 (23.8%) patients, whom 20 reported positive test. Eleven (55%) testing for after being vaccinated. Median was 80% 60-100%), subjective full 30% (6/20) who Of tested COVID-19, 5 receiving belimumab, 1 tocilizumab, 2 4 rituximab. all respondents, three individuals hospitalised one required an ICU admission. those hospitalised, unvaccinated infection, other patient vaccination. Four/1387 registered confirmed have died since beginning Conclusion this moderate-to-severe there low incidence infection. Despite this, PCR lateral flow test proven seen only patients. This raises concerns potential long COVID warrants further investigation. Acknowledgements Submitted on behalf BILAG-biologics register Disclosure Interests Sarah Dyball Grant/research support from: UCB Eli Lilly, Mia Rodziewicz UCB, Emily Sutton: None declared, Ben Parker Speakers bureau: Lilly Roche, Consultant of: Fresenius-Kabi AbbVie, Genzyme/Sanofi GSK, Ian N. Bruce AstraZeneca, GSK Merck Serono, ILTOO, Genzyme/Sanofi, Roche